
August 2003 Cover
|
 |
Canadian and US scientists reported last month that people who stay healthy years after HIV infection are more likely than other HIV patients to be infected with virus that has a particular protein alteration. The finding offers another possible explanation why a small number of
people with HIV never develop AIDS, and points toward new therapies that might prevent the progression of HIV in other patients, as well.
Experiments with an HIV protein-- viral protein R (Vpr)-- revealed that altering or deleting the protein greatly decreased the number of immune cells destroyed by HIV, the process that enables HIV to progress to AIDS. Treatments that block Vpr may help infected people
to stay healthy, said study author Dr. Andrew Badley of the Mayo Clinic in Rochester, Minnesota.
In the small number of HIV patients known as nonprogressors, levels of the virus remain low, even without treatment, and AIDS does not develop. Badley and colleagues examined the makeup of HIV extracted from the blood of people with HIV, some of whom
were nonprogressors. Once researchers identified that a particular HIV mutation was present more often in nonprogressors, they designed HIV samples that contain normal or mutated forms of Vpr, and some samples lacking the protein. Badley and his team then mixed those
different forms of HIV with human blood cells, and discovered that each type of virus had a different effect on immune cells.
"The amount of cell death was minimal in the virus that did not have Vpr, was quite high in the virus that contained normal Vpr, and was kind of halfway in between in the virus that contained the mutant Vpr," Badley said.
Badley explained that HIV in nonprogressors likely succeeds in killing immune cells, but at such a slow rate, people are able to make new immune cells fast enough that their immune system does not become compromised. He noted that he and his colleagues are currently
looking at developing Vpr inhibitors.
Editor's Note: from Reuters Health
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|